![]() Quasar's earnings before interest, taxes, depreciation and amortization was about $30 million in 2022, said one of the sources and a seventh source with knowledge of the transaction. Longreach acquired a controlling stake in the company in 2019 for an undisclosed amount. It has two manufacturing facilities in China and one in Thailand, the website showed. Quasars earnings before interest, taxes, depreciation and amortization was about 30 million in 2022, said one of the sources and a seventh source with knowledge of the transaction. The sale process comes at a time where medical services companies are gaining favour, as investors bet on the healthcare sector's ability to weather the challenging global economic environment.Įstablished in 1988 in Israel, Quasar is a global contract development and manufacturing organization (CDMO) of advanced medical devices and counts Johnson & Johnson JNJ and Medtronic PLC MDT as clients, according to the company's website. Private equity firm General Atlantic and a number of strategic buyers are also in the fray, said the fourth source and two separate people with knowledge of the matter. BPEA EQT and Goldman declined to comment.īidders are currently doing due diligence on the company, according to two of the sources, one of whom added that final bids are due by end of June. Longreach, Quasar, Boyu and Hillhouse did not respond to a request for comment. The bidding process, which is being run by Goldman Sachs, has entered the second round, the first three sources said.Īll the sources declined to be identified as the deal talks are confidential. Quasar is a leading provider of end-to-end manufacturing solutions in the medical device industry. ![]() Longreach, an Asia-focused private equity firm, is targeting a valuation of as much as $600 million or more for the entire company, said one of the three sources and a separate person with knowledge of the transaction. For more than 35 years, Quasar has been at the forefront of medical device manufacturing, leveraging state-of-the-art facilities and an unparalleled workforce to specialize in the design, development, and production of minimally invasive devices. Private equity firms Boyu Capital, Hillhouse Capital and BPEA EQT are among bidders vying for Longreach Group's Hong Kong-based medical device maker Quasar, three people with knowledge of the matter said.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |